国办印发《国家组织药品集中采购和使用试点方案》

2019-01-18 佚名 新华社

国务院办公厅日前印发《国家组织药品集中采购和使用试点方案》(以下简称《方案》),对国家组织药品集中采购和使用试点工作作出部署。

国务院办公厅日前印发《国家组织药品集中采购和使用试点方案》(以下简称《方案》),对国家组织药品集中采购和使用试点工作作出部署,选择北京、天津、上海、重庆和沈阳、大连、厦门、广州、深圳、成都、西安11个城市开展试点工作。
《方案》指出,根据党中央、国务院部署,为深化医药卫生体制改革,完善药品价格形成机制,开展国家组织药品集中采购和使用试点。目标任务是实现药价明显降低,减轻患者药费负担;降低企业交易成本,净化流通环境,改善行业生态;引导医疗机构规范用药,支持公立医院改革;探索完善药品集中采购机制和以市场为主导的药品价格形成机制。
《方案》提出,要按照国家组织、联盟采购、平台操作的总体思路,即国家拟定基本政策、范围和要求,组织试点地区形成联盟,以联盟地区公立医疗机构为集中采购主体,探索跨区域联盟集中带量采购。
《方案》明确,从通过质量和疗效一致性评价的仿制药对应的通用名药品中遴选试点品种。经国家药品监督管理部门批准、在中国大陆地区上市的集中采购范围内药品的生产企业,均可参加试点。具体措施如下:
一是带量采购,以量换价。按照试点地区所有公立医疗机构年度药品总用量的60%-70%估算采购总量,进行带量采购,量价挂钩、以量换价,形成药品集中采购价格,试点城市公立医疗机构或其代表根据上述采购价格与生产企业签订带量购销合同。二是招采合一,保证使用。试点地区公立医疗机构应优先使用中选药品,确保1年内完成合同用量。三是确保质量,保障供应。要严格执行质量入围标准和供应入围标准,建立对入围企业产品质量和供应能力的调查、评估、考核、监测体系。四是保证回款,降低交易成本。医疗机构作为药款结算第一责任人,应按合同规定与企业及时结算,降低企业交易成本。严查医疗机构不按时结算药款问题。医保基金在总额预算的基础上,按不低于采购金额的30%提前预付给医疗机构。有条件的城市可试点医保直接结算。
为保障试点政策落地,《方案》要求做好政策衔接,实现三医联动。一是探索试点城市医保支付标准与采购价协同。二是通过机制转化,促进医疗机构改革。三是压实医疗机构责任,确保用量。四是明确部门职责,做好政策衔接。
下一步,试点地区要在省级采购平台上按照集中采购价格完成挂网,于2019年初开始执行集中采购结果。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1641680, encodeId=990b164168066, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Oct 23 15:59:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694308, encodeId=07cc16943087a, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Mon Mar 04 18:59:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460112, encodeId=689f1460112ba, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Sun Jan 20 01:59:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532802, encodeId=382015328021e, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sun Jan 20 01:59:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1641680, encodeId=990b164168066, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Oct 23 15:59:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694308, encodeId=07cc16943087a, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Mon Mar 04 18:59:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460112, encodeId=689f1460112ba, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Sun Jan 20 01:59:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532802, encodeId=382015328021e, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sun Jan 20 01:59:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1641680, encodeId=990b164168066, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Oct 23 15:59:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694308, encodeId=07cc16943087a, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Mon Mar 04 18:59:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460112, encodeId=689f1460112ba, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Sun Jan 20 01:59:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532802, encodeId=382015328021e, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sun Jan 20 01:59:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1641680, encodeId=990b164168066, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Oct 23 15:59:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694308, encodeId=07cc16943087a, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Mon Mar 04 18:59:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460112, encodeId=689f1460112ba, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Sun Jan 20 01:59:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532802, encodeId=382015328021e, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sun Jan 20 01:59:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-01-20 wolongzxh

相关资讯

国家医保局回应集中采购热点

12月8日,国家医疗保障局对外发布信息,对国家组织药品集中采购和使用试点工作所涉及的热点进行回应。

药品集中采购拟中选结果惹质疑 国家医保局回应

12月7日,国家组织“4+7”城市药品集中采购试点拟中选结果公布,并对外进行为期一周的公示。一时间,各方解读纷至沓来,有叫好也有忧虑与质疑。8日,国家医疗保障局对集中采购热点问题进行回应。拟中选结果显示,31个试点通用名药品有25个集中采购拟中选,成功率81%。其中,通过一致性评价的仿制药22个,占88%,原研药3个,占12%。与试点城市去年同种药品最低采购价相比,拟中选价平均降幅52%,最高

“4+7”为政策联动开了好头

在各方热议中,第一次由国家组织的药品集中采购基本落下帷幕。“专利过期原研药保持高价、占据市场的时代终结”“仿制药高价格、高毛利、不规范销售的时代终结”,其重要意义从各种言论中可见一斑。而放在持续推动医改发展的进程中来看,首次国家药品集中采购仍有许多改革命题有待研究。

11城试点药品集中采购,易瑞沙、格列卫等抗癌药或大幅降价

日前,4+7城市药品集中采购拟中选结果对外公布。据国家组织药品集中采购试点工作联合采购办公室介绍,与试点城市2017年同种药品最低采购价相比,25种药品拟中选价平均降幅达52%,原研药吉非替尼片降价76%。哪些城市进入试点?——北京等11城试点 或占全国三分之一市场上月,中央全面深化改革委员会第五次会议审议通过《国家组织药品集中采购试点方案》,明确了国家组织、联盟采购、平台操作的总体思路。11个试

国办发文!药品集中采购推向全国

近日,国务院办公厅印发国家组织药品集中采购和使用试点方案的通知,业内人士认为,这是国家下定决心全国推广4+7带量采购了。

国家药品集中采购北京等11城市试点

国务院办公厅日前印发《国家组织药品集中采购和使用试点方案》(以下简称《方案》),对国家组织药品集中采购和使用试点工作作出部署